Bradykinin Receptor Antagonist

Aka: Bradykinin Receptor Antagonist, Bradykinin B2 Receptor Antagonist, Bradykinin B2 inhibitor, Icatibant, Firazyr

advertisement

II. Indications

  1. Severe, airway compromising Angioedema
    1. Hereditary Angioedema (treatment of choice)
    2. ACE InhibitorAngioedema (may be effective, off label use)

III. Mechanism

  1. Selective Bradykinin B2 Receptor Antagonist

IV. Dosing

  1. Initial Dose: 30 mg SQ
  2. Second Dose: 30 mg SQ at 6 hours after first if inadequate response to the initial dose
  3. Maximum: 90 mg total daily dose
  4. Cost: $10,000 per 30 mg dose

V. Adverse Effects

  1. Local skin reaction (97%)
  2. Dizziness (3%)
  3. Fever (4%)

VI. References

  1. (2015) Lexicomp, accessed online 4/9/2015
  2. Bas (2015) N Engl J Med 372(5):418-25 +PMID:25629740 [PubMed]

Images: Related links to external sites (from Bing)

These images are a random sampling from a Bing search on the term "Bradykinin Receptor Antagonist." Click on the image (or right click) to open the source website in a new browser window. Search Bing for all related images

Related Studies (from Trip Database) Open in New Window

Ontology: icatibant (C0246269)

Concepts Pharmacologic Substance (T121) , Amino Acid, Peptide, or Protein (T116)
MSH C065679
SnomedCT 703834005
English D-Arg(Hyp(3)-Thi(5)-D-Tic(7)-Oic(8))BK, icatibant, ICATIBANT, L-Arginine, D-arginyl-L-arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-D-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl-L-(2alpha,3abeta,7abeta)-octahydro-1H-indole-2-carbonyl-, Icatibant, Icatibant (substance)
Derived from the NIH UMLS (Unified Medical Language System)

Ontology: Bradykinin B2 inhibitor (C3839089)

Concepts Pharmacologic Substance (T121)
SnomedCT 703833004
English Bradykinin B2 inhibitor (substance), Bradykinin B2 inhibitor
Derived from the NIH UMLS (Unified Medical Language System)

Ontology: Bradykinin Receptor Antagonists (C3850094)

Definition (MSH) Compounds and drugs that inhibit ligand binding or cellular signaling by BRADYKININ RECEPTORS.
Concepts Pharmacologic Substance (T121)
MSH D065168
English Bradykinin Receptor Blockers, Inhibitors, Bradykinin Receptor, Receptor Antagonists, Bradykinin, Receptor Blockers, Bradykinin, Bradykinin Antagonists, Antagonists, Bradykinin, Antagonists, Bradykinin Receptor, Receptor Inhibitors, Bradykinin, Bradykinin Receptor Inhibitors, Bradykinin Receptor Antagonists
Derived from the NIH UMLS (Unified Medical Language System)

Ontology: Bradykinin B2 Receptor Antagonists (C3850105)

Definition (MSH) Compounds and drugs that inhibit ligand binding or cellular signaling by BRADYKININ B2 RECEPTORS.
Concepts Pharmacologic Substance (T121)
MSH D065094
English Bradykinin B2 Antagonists, B2 Antagonists, Bradykinin, Bradykinin B2 Receptor Inhibitors, Bradykinin B2 Receptor Blockers, Antagonists, Bradykinin B2, Bradykinin B2 Receptor Antagonists
Derived from the NIH UMLS (Unified Medical Language System)

Related Topics in Pharmacology

advertisement

2019 Family Practice Notebook, LLC. Terms | Privacy (EHS) | About | Site Map | Blog

Footer Site Logo